Gastrointestinal manifestations of dermatologic disorders

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 9, 2007, Pages 1010-1017

  Shields, Helen M ^a   Shaffer, Kitt ^a   O'Farrell, Richard P ^a   Travers, Robin ^b   Hayward, Jane N ^a   Becker, Laren S ^a   Lauwers, Gregory Y ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Skincare Associates   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AGED; ARTICLE; BIOPSY; CASE REPORT; COLON DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DUODENUM DISEASE; EPIDERMOLYSIS BULLOSA; ESOPHAGUS STENOSIS; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTESTINE MUCOSA; INTESTINE TUMOR; JEJUNUM DISEASE; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; RENDU OSLER WEBER DISEASE; SKIN TUMOR; SMALL INTESTINE; SYSTEMIC MASTOCYTOSIS;

ADOLESCENT; AGED; AGED, 80 AND OVER; BIOPSY; COLONIC DISEASES; DIAGNOSIS, DIFFERENTIAL; DUODENAL DISEASES; ENDOSCOPY, GASTROINTESTINAL; EPIDERMOLYSIS BULLOSA; ESOPHAGEAL STENOSIS; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTESTINAL MUCOSA; INTESTINAL NEOPLASMS; INTESTINE, SMALL; JEJUNAL DISEASES; MASTOCYTOSIS, SYSTEMIC; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 35748959061     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.05.018     Document Type: Review

References (96)

1. Marinkovich MP, Khavari PA, Herron GS, et al. Inherited epidermolysis bullosa. In: Fitzpatrick TB, Freedberg IM, eds. Fitzpatrick's Dermatology in general medicine. 6th ed. New York: McGraw-Hill, Medical Pub. Division, 2003:596-609.
2. Fine J-D. Epidermolysis Bullosa. In: Bolognia J, Jorizzo JL, Rapini RP, eds. Dermatology. London: Mosby, 2003:491-500.
3. Johnston GA, Graham-Brown RAC. The skin and disorders of the alimentary tract and the hepatobiliary system. In: Fitzpatrick TB, Freedberg IM, eds. Fitzpatrick's Dermatology in general medicine. 6th ed. New York: McGraw-Hill, Medical Pub. Division, 2003: 1609-1622.
4. Jorizzo JL, Sherertz EF, Bennett ML. Skin lesions associated with gastrointestinal diseases. In: Yamada T, Alpers DH, eds. Textbook of gastroenterology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 1999:992-1007.
5. Mirowski G, Chuang T-Y. Oral disease and oral manifestations of gastrointestinal and liver diseases. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal and liver disease: pathophysiology, diagnosis, management. Volume [7th] ed. Philadelphia: Saunders, 2002:339-358.
6. Pulkkinen L, Rouan F, Bruckner-Tuderman L, et al. Novel ITGB4 mutations in lethal and nonlethal variants of epidermolysis bullosa with pyloric atresia: missense versus nonsense. Am J Hum Genet 1998;63:1376-1387.
7. Muller FB, Kuster W, Wodecki K, et al. Novel and recurrent mutations in keratin KRT5 and KRT14 genes in epidermolysis bullosa simplex: implications for disease phenotype and keratin filament assembly. Hum Mutat 2006;27:719-720.
8. Bello Y, Falabella AF, Schachner LA. Epidermolysis bullosa. In: Lebwohl M, ed. Treatment of skin disease: comprehensive therapeutic strategies. 2nd ed. Philadelphia: Mosby/Elsevier, 2006: 188-190.
9. Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified stem cells. Nat Med 2006;12:1397-1402.
10. Ferrari S, Pellegrini G, Mavilio F, et al. Gene therapy approaches for epidermolysis bullosa. Clin Dermatol 2005;23:430-436.
11. Anderson SH, Meenan J, Williams KN, et al. Efficacy and safety of endoscopic dilation of esophageal strictures in epidermolysis bullosa. Gastrointest Endosc 2004;59:28-32.
12. Castillo RO, Davies YK, Lin YC, et al. Management of esophageal strictures in children with recessive dystrophic epidermolysis bullosa. J Pediatr Gastroenterol Nutr 2002;34:535-541.
13. Azizkhan RG, Stehr W, Cohen AP, et al. Esophageal strictures in children with recessive dystrophic epidermolysis bullosa: an 11-year experience with fluoroscopically guided balloon dilatation. J Pediatr Surg 2006;41:55-60.
14. Thornton RH, Heyman MB, Wilson MW, et al. Sharp recanalization of a short esophageal occluding stricture in a patient with epidermolysis bullosa. Gastrointest Endosc 2006;64:793-796.
15. Demirogullari B, Sonmez K, Turkyilmaz Z, et al. Colon interposition for esophageal stenosis in a patient with epidermolysis bullosa. J Pediatr Surg 2001;36:1861-1863.
16. Valent P. Mastocytosis (mast cell disease). In: Jaffe E, Harris NL, Stein H, and Vardiman JW, eds. Pathology and genetics of tumorsof the haemaopoietic and lymphoid tissues. Volume 1. Lyon: IARC Press, 2001:291-302.
17. Caplan RM. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. Arch Dermatol 1963;87:146-157.
18. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-625.
19. Soter NA. Mastocytosis and the skin. Hematol Oncol Clin North Am 2000;14:537-555, vi.
20. Hartmann K, Henz BM. Classification of cutaneous mastocytosis: a modified consensus proposal. Leuk Res 2002;26:483-486.
21. Middelkamp Hup MA, Heide R, Tank B, et al. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol 2002;16:115-120.
22. Lawrence JB, Friedman BS, Travis WD, et al. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991;91:612-624.
23. Travis WD, Li CY, Bergstralh EJ, et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988;67:345-368.
24. Horny HP, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol 1985;16:808-814.
25. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's hospital. J Invest Dermatol 1991;96:5S-14S.
26. Cherner JA, Jensen RT, Dubois A, et al. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology 1988;95:657-667.
27. Cherner JA. Gastric acid secretion in systemic mastocytosis. N Engl J Med 1989;320:1562.
28. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. kit mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-2372.
29. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 1999;96:1609-1614.
30. Pignon JM, Giraudier S, Duquesnoy P, et al. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997; 96:374-376.
31. Hartmann K, Wardelmann E, Ma Y, et al. Novel germline mutation of kit associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 2005;129:1042-1046.
32. Tang X, Boxer M, Drummond A, et al. A germline mutation in kit in familial diffuse cutaneous mastocytosis. J Med Genet 2004; 41:e88.
33. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103:3222-3225.
34. Beghini A, Tibiletti MG, Roversi G, et al. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001; 92:657-662.
35. Zhang LY, Smith ML, Schultheis B, et al. A novel K509I mutation of kit identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30:373- 378.
36. Brunning RD, McKenna RW, Rosai J, et al. Systemic mastocytosis. Extracutaneous manifestations. Am J Surg Pathol 1983;7: 425-438.
37. Stevens EC, Rosenthal NS. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease. Am J Clin Pathol 2001;116:177-182.
38. Horny HP, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998;22:1132-1140.
39. Horny HP, Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 2002;127: 115-117.
40. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319-1325.
41. Valent P, Schernthaner GH, Sperr WR, et al. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev 2001;179:74-81.
42. Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987;316:1622-1626.
43. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001;98:2200-2209.
44. Sperr WR, Hauswirth AW, Valent P. Tryptase a novel biochemical marker of acute myeloid leukemia. Leuk Lymphoma 2002;43: 2257-2261.
45. Sperr WR, Stehberger B, Wimazal F, et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002;43:1097-1105.
46. Samorapoompichit P, Kiener HP, Schernthaner GH, et al. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001;98:2580-2583.
47. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002; 119:1090-1097.
48. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005;114: 26-40.
49. Tefferi A, Li CY, Butterfield JH, et al. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001;344:307-309.
50. Pardanani A, Hoffbrand AV, Butterfield JH, et al. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004;28:127-131.
51. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003;102:4270- 4276.
52. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003;362:535-536.
53. Musto P, Falcone A, Sanpaolo G, et al. Inefficacy of imatinibmesylate in sporadic, aggressive systemic mastocytosis. Leuk Res 2004;28:421-422.
54. Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990; 85:852-855.
55. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000;14: 579-623.
56. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66-67.
57. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995;333:918-924.
58. Sadick H, Sadick M, Gotte K, et al. Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures. Wien Klin Wochenschr 2006;118:72-80.
59. Garcia-Tsao G. Liver Involvement in hereditary hemorrhagic telangiectasia (HHT). J Hepatol 2007;46:499-507.
60. Korzenik J, Chung DC, Digumarthy S, et al. Case records of theMassachusetts General Hospital. Case 33-2005. A 43-year-old man with lower gastrointestinal bleeding. N Engl J Med 2005;353:1836-1844.
61. Gallione CJ, Repetto GM, Legius E, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363:852-859.
62. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005; 90:818-828.
63. Sadick H, Naim R, Gossler U, et al. Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int J Mol Med 2005;15:15-19.
64. Cole SG, Begbie ME, Wallace GM, et al. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome J Med Genet 2005;42:577-582.
65. Cirulli A, Liso A, D'Ovidio F, et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 2003;110:29-32.
66. Gallitelli M, Pasculli G, Fiore T, et al. Emergencies in hereditary haemorrhagic telangiectasia. QJM 2006;99:15-22.
67. Saba HI, Morelli GA, Logrono LA. Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N Engl J Med 1994;330:1789-1790.
68. Sabba C, Gallitelli M, Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:926.
69. Longacre AV, Gross CP, Gallitelli M, et al. Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2003;98:59-65.
70. Ingrosso M, Sabba C, Pisani A, et al. Evidence of small-bowel involvement in hereditary hemorrhagic telangiectasia: a capsuleendoscopic study. Endoscopy 2004;36:1074-1079.
71. Van Cutsem E, Rutgeerts P, Vantrappen G. Long-term effect of hormonal therapy for bleeding gastrointestinal vascular malformations Eur J Gastroenterol Hepatol 1993;5:439-443.
72. Inouye P, Marcon N, Pugash RA, et al. Embolization of a duodenal arteriovenous malformation in hereditary hemorrhagic telangiectasia: case report and review of the literature. Can J Gastroenterol 2003;17:661-665.
73. Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999;54:714-729.
74. Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2006;3: CD004434.
75. Larson AM. Liver disease in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 2003;36:149-158.
76. Thevenot T, Vanlemmens C, Di Martino V, et al. Liver transplantation for cardiac failure in patients with hereditary hemorrhagic telangiectasia. Liver Transpl 2005;11:834-838.
77. Lerut J, Orlando G, Adam R, et al. Liver transplantation for hereditary hemorrhagic telangiectasia: report of the European Liver Transplant Registry. Ann Surg 2006;244:854-864.
78. Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic tealangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006;85:631-632.
79. Massoud OI, Youssef WI, Mullen KD. Resolution of hereditary hemorrhagic telangiectasia and anemia with prolonged alphainterferon therapy for chronic hepatitis C. J Clin Gastroenterol 2004;38:377-379.
80. Wheatley-Price P, Shovlin C, Chao D. Interferon for metastatic renal cell cancer causing regression of hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 2005;39:344-345.
81. Nestle F. Melanoma. In: Bolognia JL, ed. Dermatology. Volume 2. London: Mosby, 2003:1789-1815.
82. Langley R. Neoplasms: cutaneous melanoma. In: Freedberg IM, ed. Fitzpatrick's Dermatology in general medicine. Volume 1. 6th ed. New York: McGraw-Hill, Medical Pub. Division, 2003:917- 947.
83. Cummins DL, Cummins JM, Pantle H, et al. Cutaneous malignant melanoma. Mayo Clin Proc 2006;81:500-507.
84. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687-701.
85. Dasgupta TK, Brasfield RD. Metastatic melanoma of the gastrointestinal tract. Arch Surg 1964;88:969-973.
86. Patel JK, Didolkar MS, Pickren JW, et al. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978;135:807-810.
87. Schuchter LM, Green R, Fraker D. Primary and metastatic diseases in malignant melanoma of the gastrointestinal tract. Curr Opin Oncol 2000;12:181-185.
88. Bender GN, Maglinte DD, McLarney JH, et al. Malignant melanoma: patterns of metastasis to the small bowel, reliability of imaging studies, and clinical relevance. Am J Gastroenterol 2001;96:2392-2400.
89. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-2147.
90. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
91. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
92. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
93. Tripp J. Malignant melanoma. In: Lebwohl M, ed. Treatment of skin disease: comprehensive therapeutic strategies. 2nd ed. Philadelphia: Mosby/Elsevier, 2006:387-389.
94. Liang KV, Sanderson SO, Nowakowski GS, et al. Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc 2006;81:511-516.
95. Damian DL, Fulham MJ, Thompson E, et al. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325-329.
96. Ollila DW, Essner R, Wanek LA, et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 1996;131:975-980.